According to Fixygen, PJSC “Pharmaceutical Company “Darnitsa” will hold its annual shareholders’ meeting on April 24, 2026, in Kyiv. In the published notice, the company listed 12 agenda items, including the CEO’s report for 2025, the supervisory board’s report, approval of financial and operational results and annual information, review of the audit report, profit distribution, preliminary approval of significant transactions for 2026–2027, amendments to the charter, as well as the termination of powers and re-election of the supervisory board and approval of contract terms with its members.
Darnitsa is one of Ukraine’s largest pharmaceutical companies and one of the country’s best-known manufacturers of medicines.
The company was founded in 1930 and produces a wide range of prescription and over-the-counter drugs.
Its production facilities and headquarters are located in Kyiv. The company remains a privately held Ukrainian pharmaceutical group with a strong position in the domestic market.
https://www.fixygen.ua/news/20260331/darnitsya-provede-zbori-aktsioneriv-24-kvitnya.html
The pharmaceutical company PrJSC Darnitsa (Kyiv) has registered a drug in Bosnia and Herzegovina for the treatment and prevention of neuromuscular transmission disorders, including myasthenia gravis, stimulation of the intestines and bladder after surgery, and restoration of muscle activity after anesthesia.
According to a press release from the company, the drug was registered at the end of December.
The registration certificate is valid for five years.
As previously reported, Darnitsa also registered an antifungal drug in Bosnia and Herzegovina.
Currently, Darnitsa’s drugs are available in more than 20 countries around the world.
Darnitsa has been operating on the market for over 90 years, is one of the ten largest pharmaceutical manufacturers in Ukraine, and produces 180 brands of drugs in 15 different forms. The strategic areas of portfolio development are cardiology, neurology, and pain management.
The net loss of PJSC “Pharmaceutical Firm ”Darnitsa“” (Kyiv) in January-June 2025 amounted to UAH 479.473 million, while in the same period of 2024, the company received a net profit of UAH 6.528 million. According to the Unified State Register of Legal Entities and Individual Entrepreneurs, the ultimate beneficiary of the company is Gleb Zagoriy.
The net loss of PJSC Pharmaceutical Company Darnitsa (Kyiv) in January-June 2025 amounted to UAH 479.473 million, while in the same period of 2024, the company received UAH 6.528 million in net profit.
According to the company’s disclosure to the National Securities and Stock Market Commission, the net loss from sales in the first half of 2025 amounted to UAH 380.233 million, while in the same period of 2024, the profit from sales amounted to UAH 119.452 million.
As reported, Darnitsa’s net loss in January-March 2025 amounted to UAH 231.077 million, while in the same period of 2024, the company received UAH 19.484 million in net profit. Net sales revenue for the first quarter of 2025 decreased by 17.4% to almost UAH 1.018 billion.
In 2024, Darnitsa registered 10 drugs outside Ukraine and entered six new markets, including EU countries, Bosnia and Herzegovina, Israel, New Zealand, and Malaysia. In total, Darnitsa’s drugs are represented in more than 20 countries around the world.
At the end of 2024, exports accounted for 3.5% of the company’s sales. At the end of 2023, exports accounted for 4%. Exports were made to 17 countries.
Darnitsa has been present on the market for over 90 years, is one of the top 10 pharmaceutical manufacturers in Ukraine, and produces 180 brands of medicines in 15 different forms. The strategic areas of portfolio development are cardiology, neurology, and pain management.
According to the Unified State Register of Legal Entities and Individual Entrepreneurs, the ultimate beneficiary of the company is Gleb Zagoriy.
PJSC “Pharmaceutical firm ”Darnitsa” (Kiev) has suspended production due to overcrowding of warehouses, which arose due to a conflict with pharmacy chains.
As the Economic Pravda newspaper reported, the company’s warehouses are “filled to overflowing due to the unwillingness of the largest pharmacy chains to sell the company’s products”.
The Interfax-Ukraine agency contacted the company to comment on the situation, but has not yet received a response.
Darnitsa Pharmaceutical Company is the leader of the Ukrainian pharmaceutical market in physical terms. The company has been on the market for over 90 years and produces 180 brands of medicines in 15 different forms. The strategic directions of portfolio development are cardiology, neurology, pain management.
The ultimate beneficiary of the company is Gleb Zagoriy.
PrJSC “Pharmaceutical Firm “Darnitsa” will establish a representative office in Uzbekistan, the company reported in the information disclosure system of the National Securities and Stock Market Commission (NSSMC).
It is specified that, according to the decision of the Supervisory Board of Darnitsa adopted on July 12, the representative office will be established “in connection with the constant development”.
As reported, in 2023, Darnitsa increased its share of exports to 4%. The company exports its products to 17 countries. In particular, thanks to the confirmation of the stability of medicines in the southern climate zone and compliance in Australia, the company can expand cooperation with New Zealand, Malaysia, Yemen and South Africa. At the same time, in 2016, Darnitsa stopped exporting to the Russian Federation, and after February 24, 2022, to Belarus.
In June 2023, Darnitsa registered one of its medicines in Australia, which, according to the company, is known for some of the strictest regulatory rules in the world.
In 2023, the company increased its net income from operating activities by 32.8% compared to 2022 to UAH 6.969 billion. The company named new products and higher selling prices as the main factors of the increase in revenue.
“Darnitsa” is the leader of the Ukrainian pharmaceutical market in physical terms. The company has been present on the market for over 90 years and produces medicines of 180 brands in 15 different forms. The strategic areas of development of the portfolio are cardiology, neurology, and pain management. According to the Unified State Register of Legal Entities and Individual Entrepreneurs, the ultimate beneficiary of the company is Hlib Zagoriy.
Darnytsa (Kyiv) pharmaceutical company in 2022 slightly reduced the production of drugs in physical terms – from 181 mln packs in 2021 to 173 mln packs in 2022, as the company informed Interfax-Ukraine news agency.
At the same time, according to its press release, Darnitsa occupies 15.7% of the Ukrainian pharmaceutical market, twice as much as its closest competitor.
“If in 2021 every seventh pack of drugs sold in pharmacies was made by “Darnitsa”, then in 2022 it is every sixth pack,” – according to the press release.
In total, in 2022 the company produced about 19 million packages of ampoules, 9 million packages of infusion solutions and 130 million packages of tablets and capsules.
At the same time, it is noted that “Darnitsa” has not stopped working since the first days of the full-scale war. In March it produced 60% of the pre-war volume of drugs, and in April it returned to pre-war production volumes in full.
PJSC “Pharmaceutical company “Darnitsa” is the leader of Ukrainian pharmaceutical market in physical terms. The company has been on the market for more than 90 years and manufactures 180 brands of drugs in 15 different forms. Strategic directions of portfolio development – cardiology, neurology, pain management.
The company was founded in 1930. According to the Uniform State Register of Legal Entities and Individual Entrepreneurs, the company’s ultimate beneficiary is Gleb Zagori.
